Oncoinvent (ONCIN)

[Hotdog]

Søk det opp så forstår du nok hva jeg mener.

[hybrid]

Skjønner hva det betyr ja

Men hva er din take rundt utsagnet isolert sett for dette selskapet, siden pensjonisten rådes på dette diffuse viset?

[TekBot]

Oncoinvent ASA: Last day of trading in subscription rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

25 November 2025: Reference is made to the stock exchange announcements
published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025,
and subsequent announcements, regarding the contemplated fully underwritten
rights issue of 260,000,000 new shares in the Company (the “Offer Shares”)
raising gross proceeds of NOK 130 million (the “Rights Issue”).

The period for trading in the subscription rights in the Rights Issue (the
“Subscription Rights”) with ticker “ONCIT” will expire today, on 25 November
2025 at 16:30 hours (CET).

The subscription period for the Rights Issue (the “Subscription Period”) expires
at 16:30 hours (CET) on 1 December 2025.

Subscription Rights that are not sold before close of trading today, on 25
November 2025 at 16:30 hours (CET) or not used to subscribe for Offer Shares
before the expiry of the Subscription Period will have no value and will lapse
without compensation to the holder.

Subscriptions for Offer Shares must be made within the expiry of the
Subscription Period and may either be made through the VPS online subscription
system or by submitting a correctly completed subscription form to ABG Sundal
Collier AS or DNB Carnegie, a part of DNB Bank ASA (acting as managers for the
Rights Issue, the “Managers”).

For more information, and the complete terms and conditions of the Rights Issue,
please refer to the prospectus dated 28 October 2025 prepared by the Company and
approved by the Financial Supervisory Authority of Norway (Nw. Finanstilsynet)
(the “Prospectus”). Subject to applicable local securities law, the Prospectus,
including the subscription form for the Rights Issue, is available at
https://www.abgsc.com/transactions and https://www.dnb.no/emisjoner.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email:(soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases in the peritoneum post-surgery, harnessing the benefits of
modern radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial in ovarian cancer is
currently ongoing in the US and Europe. Early clinical efficacy data are highly
encouraging, and no serious toxicity or safety concerns have been reported to
date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo
Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly
target microscopic metastases in the abdominal cavity following surgery.
Radspherin® is currently in development as a post-surgical treatment for
patients with cancer that has spread to the abdominal cavity - a group with very
limited treatment options today. The drug candidate offers a distinctly unique
therapeutic approach with several differentiating features, including the use of
radium-224, single-dose treatment with a sustained therapeutic effect, non
-systemic administration, direct targeting and an exceptional dose-to-tumor
ratio, maximizing efficacy while limiting harm to healthy tissue

IMPORTANT INFORMATION

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this document may not be sent to
jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The securities of the Company may not be offered or
sold in the United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”).

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified institutional
buyers” as defined in Rule 144A under the U.S. Securities Act. No public
offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made by
means of the Prospectus prepared by the Company in connection the Rights Issue,
as approved by the The Financial Supervisory Authority of Norway (Nw.
Finanstilsynet) on 28 October 2025. This announcement is an advertisement and is
not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European
Parliament and of the Council of 14 June 2017 on prospectuses to be published
when securities are offered to the public or admitted to trading on a regulated
market, and repealing Directive 2003/71/EC (as amended) as implemented in any
EEA Member State (the “Prospectus Regulation”). Investors should not subscribe
for any securities referred to in this announcement except on the basis of
information contained in the Prospectus. Copies of the Prospectus is available
from the Company’s registered office and, subject to certain exceptions, on the
website of the Managers.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

This document is not for publication or distribution in, directly or indirectly,
Australia, Canada, Japan, the United States or any other jurisdiction in which
such release, publication or distribution would be unlawful, and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States or to publications with a general circulation in the
United States of America.

The Managers are acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their respective clients or for providing
advice in relation to the Rights Issue or any transaction or arrangement
referred to in this announcement. Matters discussed in this announcement may
constitute forward-looking statements. Forward-looking statements are statements
that are not historical facts and may be identified by words such as
“anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”,
“should”, “will” and similar expressions. The forward-looking statements in this
release are based upon various assumptions, many of which are based, in turn,
upon further assumptions.

Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date and are
subject to change without notice. This announcement is made by and is the
responsibility of, the Company. Neither the Managers nor any of their affiliates
makes any representation as to the accuracy or completeness of this announcement
and none of them accepts any responsibility for the contents of this
announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. No reliance may be
placed for any purpose on the information contained in this announcement or its
accuracy, fairness or completeness. Neither the Managers nor any of their
respective affiliates accepts any liability arising from the use of this
announcement.

Kilde

[urban66]

Hvis jeg allerede har sendt inn en tegningsbestilling på f.eks. 300 000 aksjer (basert på 200 000 forhåndsgitte TR + 100 000 overtegning), er jeg da helt låst til denne ene bestillingen? Selv om jeg i etterkant kjøper flere tegningsretter i markedet (si 600 000 stk), så kan jeg ikke bruke dem til å øke bestillingen min mellom 26.11-1.12?
Så VPS-bestillingen en engangsgreie der første innsending låser alt og bordet fanger
Noen som kan bekrefte om dette stemmer 100%, ser ut som jeg har klønet litt med TR-reglene her?

[urban66]

Spurte meg selv via AI Og kanskje andre er interessert i svaret. Og AI er meg bekjent hverken Gud eller ufeilbarig, så korrekt meg gjerne og forhåpendtligvis AI: Ja, det stemmer. Når du har sendt inn en tegningsbestilling i VPS (f.eks. 300 000 aksjer), er den låst . Du kan ikke øke bestillingen i etterkant, selv om du kjøper flere tegningsretter senere. Nye TR gir deg ingen ekstra tegningsmuligheter etter at bestillingen er sendt.
VPS-bestilling er en engangsbestilling , og «bordet fanger».

[hybrid]

Du kan annullere bestillingen på vps mener jeg.

[nhy1024]

Ja, skal bare være å kansellere den gamle bestillingen og legge inn en ny

[urban66]

AI nekter plent for dette: Det er faktisk ikke mulig. VPS har ingen funksjon for å kansellere en allerede innsendt tegningsbestilling i en emisjon. Når bestillingen er registrert, er den bindende og låst , og kan ikke slettes eller erstattes av en ny.

Dette kan du også se i VPS: det finnes verken “kanseller” eller “endre” på emisjonsordrer – kun én innsendelse.

Tilrettelegger (DNB/ABG) kan i teorien gjøre en manuell annullering, men det gjøres normalt ikke for retail og ikke etter at tegningen har åpnet.

Kort sagt: Bestillingen står, og ekstra TR du kjøper nå kan ikke brukes. Edit: Ingenting hadde gledet meg mer enn at AI tar feil

[TyrionIV]

Jeg mener ganske bestemt at du kan sende inn bestilling på nytt og da vil siste bestilling være gjeldende. Så lenge ikke fristen er gått ut så kan du endre det.

[hybrid]

Er vel bare å gå på vps å se det…

Jeg kunne annullere bestilling når jeg bestilte, ellers tror jeg tyrion er inne på noe så er jo bare å prøve.

[urban66]

Spiller forsåvidt ingen rolle slik som kursutviklingen gikk, men greit å ha kunnskapen inne til en annen gang: Ai blånekter på angrefrist fremdeles VPS-regelen (rett fra hjelpesystemet deres):

Når en tegningsordre i en emisjon er sendt inn gjennom VPS-investortjenesten, er den bindende og kan ikke endres eller annulleres av investor.
VPS viser kun:

• “Innsendt” / “Registrert”
• Ingen funksjoner for “endre” eller “kanseller” .

Endringer kan kun utføres av tilrettelegger
(DNB Markets / ABG / Carnegie), og kun før tegningen åpner , og bare i helt spesielle tilfeller.

Kilde: VPS brukerstøtte / Investor Services – “Corporate Actions / Rights Issues”.

[Boms]

Tror jeg ville dobbeltsjekket at du ikke blir stående med to tegninger. Ikke gitt at disse systemene er så smarte.

[TyrionIV]

Ja, om man tenker endre, så er det nok lurt å dobbeltsjekke og kontakte dem du tegner hos å forhøre deg.

[Tixis]

Jeg har bare lagt en ny bestilling oppe på den gamle fordi VPS konto jeg skal ha aksjene til ikke var den jeg ønsket.
Euronext godtok det og jeg fikk en ny bekreftelsesmail på bestillingen så tror d går fint å legge en ny en ja som erstatter den gamle

[Musicator]

Jeg kansellerte en av de første dagene da jeg hadde lagt in feil VPS-nummer. Så la inn med korrekt VPS-nummer. Se utdrag fra epost fra @euronext.com nedenfor (fjernet personlig info).

Din bestilling er annullert. Ved eventuelle spørsmål kontakt DNB Bank ASA , tlf. +4791504800.

Navn:
Antall aksjer:
VPS-Konto:
Bankkonto for belastning:
Aksje: NO 001 3251173 Oncoinvent ASA
Tidspunkt: 17.11.2025 kl. 22:07

[urban66]

Dette viser bare det er mulig å rette tekniske detaljer, som feil Vpskonto. Det betyr ikke at man kan endre antall bestilte aksjer, blir en helt annen ballgame.

[TyrionIV]

Jeg er helt sikker på at du kan kansellere eller endre tegningen om du ønsker. enten ved å bare sende bestillingen på nytt gjennom vps, slik jeg forespeilet over. Eller, for å være helt sikker, kontakte megler som gjennomfører emisjonen direkte og ordne det på den måten.

[Boms]

Ett pussig aksjeforum dette, aksjen er opp 31 % i dag og siste innlegg er 18 timer gammelt

La oss håpe at magnetismen i å ha en tegningskurs på 50 øre nå er opphevet

[hybrid]

Alle holder kjeft og håper den fortsetter

Uansett, all selskapsrelatert diskusjon blir klipt ned av andre brukere som vektlegger noen generelle argument og denne sagnomsuste oppvasken som foregikk.

Savner en balansert diskusjon rundt selskapet.

Forøvrig er det publisert artikler i sept/okt som omhandler OI-1(chimerisk) og litt rundt det.

Liten teaser:

Så får vi se om graveviljen vekkes i folk

[Direkte]

Av hvilken årsak stiger aksjen såpass?